W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and Prevention
The independent EGAPP working group (EWG) held its 26th meeting on February 11-12, 2013 at the CDC campus in Atlanta. Highlights included:
- Three EWG recommendation statements on the validity and utility of genetic tests are pending publication on:
- KRAS, BRAF and other markers involved in EGFR signaling, which are used to inform choice of therapies for metastatic colorectal cancer, recently published in Genetics in Medicine;
- Genetic risk assessment for type 2 diabetes in general and high-risk populations, recently accepted to Genetics in Medicine ; and
- PCA3 testing in the diagnosis and management of prostate cancer based on an evidence review, conducted through the AHRQ Effective Health Care Program (EHC), is being finalized and prepared for peer review.